
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems, Inc. has demonstrated a significant upward trajectory in its operational metrics, with therapy utilization increasing from 1.1 procedures per month in 2021 to 1.8 in 2024. The company reported Q4 revenue of $239.7 million, reflecting a year-over-year growth of 24.5%, and earnings per share of $1.15, surpassing consensus expectations. Furthermore, ongoing innovations and the planned expansion of implanting centers are expected to drive continued revenue growth and improved procedure efficiencies in the coming years, suggesting a strong outlook for the company.
Bears say
Inspire Medical Systems faces several fundamental challenges that contribute to a negative outlook on its stock, including slower penetration of implant centers, lower-than-expected utilization rates, and a delayed path to profitability. The company also encounters competitive pressures from new entrants in the market and a decline in physician reimbursement, which could hinder the adoption of its neurostimulation technology among new ENT specialists. Additionally, dependencies on its sales force and potential supply chain risks further complicate its growth prospects in a competitive landscape.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares